289 related articles for article (PubMed ID: 17966839)
1. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
Zhu Y; Statkevich P; Cutler DL
Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
[TBL] [Abstract][Full Text] [Related]
3. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Ready NE; Lipton A; Zhu Y; Statkevich P; Frank E; Curtis D; Bukowski RM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):576-83. PubMed ID: 17255280
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
Awada A; Eskens FA; Piccart M; Cutler DL; van der Gaast A; Bleiberg H; Wanders J; Faber MN; Statkevich P; Fumoleau P; Verweij J;
Eur J Cancer; 2002 Nov; 38(17):2272-8. PubMed ID: 12441264
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Karim A; Covington P; Christopher R; Davenport M; Fleck P; Li X; Wann E; Mekki Q
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):46-58. PubMed ID: 20040339
[TBL] [Abstract][Full Text] [Related]
9. Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects.
Disanto AR; Golden G
Clin Drug Investig; 2009; 29(8):539-49. PubMed ID: 19591515
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
11. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
[TBL] [Abstract][Full Text] [Related]
13. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
14. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy.
Patel CG; Rangachari L; Patti M; Griffin C; Shou Y; Venkatakrishnan K
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):637-646. PubMed ID: 30168905
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Properties of Oral Lafutidine Tablets and the Effect of Food on its Pharmacokinetics in Healthy Chinese Subjects.
Li S; Xu M; Li H; Du J; Li W
Adv Ther; 2016 Oct; 33(10):1704-1714. PubMed ID: 27444313
[TBL] [Abstract][Full Text] [Related]
17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
18. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Eskens FA; Awada A; Cutler DL; de Jonge MJ; Luyten GP; Faber MN; Statkevich P; Sparreboom A; Verweij J; Hanauske AR; Piccart M;
J Clin Oncol; 2001 Feb; 19(4):1167-75. PubMed ID: 11181683
[TBL] [Abstract][Full Text] [Related]
20. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
